Product
Acolbifene
1 clinical trial
4 indications
Indication
Breast Atypical HyperplasiaIndication
Breast CancerIndication
Breast Ductal Carcinoma In SituIndication
Lobular Carcinoma In SituClinical trial
Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-Menopausal Women at High Risk for Development of Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-09-01